Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Euronext Paris  >  BioAlliance Pharma SA    C4X   

 SummaryNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Financials (€)
Sales 2016 3,45 M
EBIT 2016 -23,6 M
Net income 2016 -23,2 M
Finance 2016 7,29 M
Yield 2016 -
Sales 2017 10,4 M
EBIT 2017 -17,3 M
Net income 2017 -17,1 M
Finance 2017 0,75 M
Yield 2017 -
P/E ratio 2016 -
P/E ratio 2017
EV / Sales2016 34,6x
EV / Sales2017 12,1x
Capitalization 127 M
More Financials
Company
Onxeo SA is a biotechnology company, which engages in the development of drugs for the treatment of orphan diseases.It produces and develops ophan oncology products under the brand names Livatag, Validive, Beleodaq, and AsiDNA.The company was founded by Gilles Avenard and Dominique Costantini on... 
Sector
Pharmaceuticals
Calendar
03/07Earnings Release
More about the company
Surperformance© ratings of BioAlliance Pharma SA
Trading Rating : Investor Rating :
More Ratings
Latest news on BIOALLIANCE PHARMA SA
01/06 EQS-NEWS : Edison issues outlook on Onxeo (ONXEO)
2016 ONXEO : to Attend Two French Investor Conferences in January
2016 ONXEO : Strengthens AsiDNA Patent Protection in Europe
2016 ONXEO : to Participate in the Guggenheim Securities 4th Annual Boston Healthcare..
2016 ONXEO COLLABORATES WITH THE ROYAL CO : Onxeo samarbejder med Royal College of Su..
2016 ONXEO : Receives USPTO Notice of Allowance for Key AsiDNATM Patent, Extending IP..
2016 ONXEO RECEIVES USPTO NOTICE OF ALLOW : Onxeo modtager “Notice of Allowance..
2016 ONXEO ADVANCES DEVELOPMENT PLAN FOR : Onxeo offentliggør udviklingsplan for det..
2016 ONXEO : advances development plan for first-in-class signal interfering DNA comp..
2016 ONXEO : Announces Development of Beleodaq Oral Formulation Opening New Opportuni..
More news
Sector news : Pharmaceuticals - NEC
12:35a U.S. reaches settlement with Endo on pay-for-delay charges
01/20 European shares ease ahead of Trump inauguration
01/20 Bristol-Myers shares fall on lung cancer timeline setback
01/19DJRival to EpiPen Allergy Treatment to Return to Market--Update
01/19DJRival to EpiPen Allergy Treatment to Return to Market
More sector news : Pharmaceuticals - NEC
Advertisement
Income Statement Evolution
More Financials
Consensus 
Mean consensus OUTPERFORM
Number of Analysts 1
Average target price 8,10 €
Spread / Average Target 201%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Judith Greciet Chief Executive Officer & Director
Joseph S. Zakrzewski Non-Executive Chairman
Nicolas Fellmann Chief Financial Officer & Secretary
Graham K. Dixon Chief Scientific Officer
David Horn Solomon Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
BIOALLIANCE PHARMA SA135
JOHNSON & JOHNSON-0.92%310 549
ROCHE HOLDING LTD.0.39%200 499
PFIZER INC.-2.19%192 792
NOVARTIS AG-4.32%185 152
MERCK & CO., INC.6.22%172 404
More Results